Bayer Gross Profit 2012-2025 | BAYRY
Bayer annual/quarterly gross profit history and growth rate from 2012 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Bayer gross profit for the quarter ending December 31, 2025 was $8.256B, a 32.59% increase year-over-year.
- Bayer gross profit for the twelve months ending December 31, 2025 was $30.297B, a 10.51% increase year-over-year.
- Bayer annual gross profit for 2025 was $30.297B, a 10.51% increase from 2024.
- Bayer annual gross profit for 2024 was $27.416B, a 9.17% decline from 2023.
- Bayer annual gross profit for 2023 was $30.183B, a 7.19% decline from 2022.
|
Bayer Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2025 | $30,297 |
| 2024 | $27,416 |
| 2023 | $30,183 |
| 2022 | $32,523 |
| 2021 | $32,257 |
| 2020 | $25,430 |
| 2019 | $29,207 |
| 2018 | $26,662 |
| 2017 | $26,712 |
| 2016 | $29,296 |
| 2015 | $27,944 |
| 2014 | $29,209 |
| 2013 | $27,642 |
| 2012 | $26,624 |
| 2011 | $25,841 |
|
Bayer Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2025-12-31 | $8,256 |
| 2025-09-30 | $6,257 |
| 2025-06-30 | $7,237 |
| 2025-03-31 | $8,547 |
| 2024-12-31 | $6,226 |
| 2024-09-30 | $5,364 |
| 2024-06-30 | $6,812 |
| 2024-03-31 | $9,013 |
| 2023-12-31 | $7,975 |
| 2023-09-30 | $6,019 |
| 2023-06-30 | $6,898 |
| 2023-03-31 | $9,291 |
| 2022-12-31 | $7,221 |
| 2022-09-30 | $7,085 |
| 2022-06-30 | $7,597 |
| 2022-03-31 | $10,619 |
| 2021-12-31 | $8,508 |
| 2021-09-30 | $6,950 |
| 2021-06-30 | $7,601 |
| 2021-03-31 | $9,199 |
| 2020-12-31 | $7,749 |
| 2020-09-30 | $2,000 |
| 2020-06-30 | $6,646 |
| 2020-03-31 | $9,034 |
| 2019-12-31 | $5,661 |
| 2019-09-30 | $6,769 |
| 2019-06-30 | $7,965 |
| 2019-03-31 | $8,813 |
| 2018-12-31 | $5,611 |
| 2018-09-30 | $6,276 |
| 2018-06-30 | $7,119 |
| 2018-03-31 | $7,657 |
| 2017-12-31 | $5,257 |
| 2017-09-30 | $6,417 |
| 2017-06-30 | $7,781 |
| 2017-03-31 | $7,257 |
| 2016-12-31 | $6,866 |
| 2016-09-30 | $7,180 |
| 2016-06-30 | $7,687 |
| 2016-03-31 | $7,562 |
| 2015-12-31 | $6,288 |
| 2015-09-30 | $6,765 |
| 2015-06-30 | $7,498 |
| 2015-03-31 | $7,394 |
| 2014-12-31 | $7,006 |
| 2014-09-30 | $6,958 |
| 2014-06-30 | $7,378 |
| 2014-03-31 | $7,867 |
| 2013-12-31 | $6,686 |
| 2013-09-30 | $6,659 |
| 2013-06-30 | $7,081 |
| 2013-03-31 | $7,216 |
| 2012-12-31 | $6,582 |
| 2012-09-30 | $6,231 |
| 2012-06-30 | $6,855 |
| 2012-03-31 | $6,956 |
| 2011-12-31 | $5,954 |
| 2011-09-30 | $6,220 |
| 2011-06-30 | $6,813 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |